eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion
top of page
Companies in the News
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant...
- Sep 28
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study
10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike...
- Sep 14
Generate:Biomedicines Announces Close of $273M Series C Financing
Funding will advance pipeline of 17 existing programs and approximately 10 new starts annually Company has raised nearly $700 million in...
- Jun 20
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc....
- May 22
EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results
Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...
- Apr 27
Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement
Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...
- Apr 13
Sana Biotechnology Announces Preclinical Data Published in Nature Communications
Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic...
- Mar 10
Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines
Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...
- Feb 16
Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...
bottom of page